Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
18 janv. 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
12 déc. 2022 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial
16 nov. 2022 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments
10 nov. 2022 08h00 HE
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 Interim Analysis on Track for Q1 2023Camsirubicin Clinical Data at CTOS 2022 Next WeekMNPR-202 Preclinical Data at ASH 2022 in December WILMETTE, Ill., Nov. 10, 2022 (GLOBE...
Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting
19 oct. 2022 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
12 oct. 2022 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
05 oct. 2022 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar to Present at Roth Inaugural Healthcare Opportunities Conference
28 sept. 2022 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments
11 août 2022 08h05 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments
12 mai 2022 08h00 HE
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward InterimCamsirubicin Phase 1b Dose-Escalation Trial Clears 3rd Dose Level, Now Enrolling 4th WILMETTE, Ill., May 12, 2022 (GLOBE...